Mariano Alberto Pennisi

Mariano Alberto Pennisi

Auto-generated profile, based on publicly available information

Mariano Alberto Pennisi

Catholic University of the Sacred Heart

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2001 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
MAM. Antonelli
M. Antonelli
GCG. Conti
G. Conti
MMM. Moro
M. Moro
AEA. Esquinas
A. Esquinas
GGG. Gonzalez-Diaz
G. Gonzalez-Diaz
GMG. Meduri
G. Meduri

1 January 2007 in Critical Care Medicine
Verified
Journal Article
Closed access
MAMassimo Antonelli
Massimo Antonelli
GCGiorgio Conti
Giorgio Conti
AEAntonio Esquinas
Antonio Esquinas
LMLuca Montini
Luca Montini
SMSalvatore Maurizio Maggiore
Salvatore Maurizio Maggiore
GMGianfranco Umberto Meduri
Gianfranco Umberto Meduri
In randomized studies of heterogeneous patients with hypoxemic acute respiratory failure, noninvasive positive pressure ventilation (NPPV) was associated with a significant reduction in endotracheal intubation. The role of NPPV in patients with acute respiratory distress syndrome (ARDS) is still unclear. The objective was to investigate the application of NPPV as a first-line intervention in patients with early ARDS, describing what happens in everyday clinical practice in centers having expertise with NPPV. Prospective, multiple-center cohort study. Three European intensive care units having expertise with NPPV. Between March 2002 and April 2004, 479 patients with ARDS were admitted to the intensive care units. Three hundred and thirty-two ARDS patients were already intubated, so 147 were eligible for the study. Application of NPPV. NPPV improved gas exchange and avoided intubation in 79 patients (54%). Avoidance of intubation was associated with less ventilator-associated pneumonia (2% vs. 20%; p < .001) and a lower intensive care unit mortality rate (6% vs. 53%; p < .001). Intubation was more likely in patients who were older (p = .02), had a higher Simplified Acute Physiology Score (SAPS) II (p < .001), or needed a higher level of positive end-expiratory pressure (p = .03) and pressure support ventilation (p = .02). Only SAPS II >34 and a Pao2/Fio2 ≤175 after 1 hr of NPPV were independently associated with NPPV failure and need for endotracheal intubation. In expert centers, NPPV applied as first-line intervention in ARDS avoided intubation in 54% of treated patients. A SAPS II >34 and the inability to improve Pao2/Fio2 after 1 hr of NPPV were predictors of failure.

4 December 2000 in Experimental Brain Research
Verified
Journal Article
Closed access
PDF file
VLVincenzo Di Lazzaro
Vincenzo Di Lazzaro
AOA. Oliviero
A. Oliviero
PPP. Profice
P. Profice
MPM. A. Pennisi
M. A. Pennisi
SGS. Di Giovanni
S. Di Giovanni
JRJohn Rothwell
John Rothwell

1 March 2002 in Critical Care Medicine
Verified
Journal Article
Closed access
MAMassimo Antonelli
Massimo Antonelli
GCGiorgio Conti
Giorgio Conti
PPPaolo Pelosi
Paolo Pelosi
CGCesare Gregoretti
Cesare Gregoretti
MPMariano Alberto Pennisi
Mariano Alberto Pennisi
RPRodolfo Proietti
Rodolfo Proietti
To assess the efficacy of noninvasive pressure support ventilation (NPSV) using a new special helmet as first-line intervention to treat patients with hypoxemic acute respiratory failure (ARF), in comparison to NPSV using standard facial mask. Prospective clinical pilot investigation with matched control group in three intensive care units of university hospitals. Thirty-three consecutive patients without chronic obstructive pulmonary disease and with hypoxemic ARF (defined as severe dyspnea at rest, respiratory rate >30 breaths/min, Pao2:Fio2 < 200, and active contraction of the accessory muscles of respiration) were enrolled. Each patient treated with NPSV by helmet was matched with two controls with ARF treated with NPSV via a facial mask, selected by simplified acute physiologic score II, age, Pao2/Fio2, and arterial pH at admission. Primary end points were the improvement of gas exchanges, the need for endotracheal intubation, and the complications related to NPSV. The 33 patients and the 66 controls had similar characteristics at baseline. Both groups improved oxygenation after NPSV. Eight patients (24%) in the helmet group and 21 patients (32%) in the facial mask group (p = .3) failed NPSV and were intubated. No patients failed NPSV because of intolerance of the technique in the helmet group in comparison with 8 patients (38%) in the mask group (p = .047). Complications related to the technique (skin necrosis, gastric distension, and eye irritation) were fewer in the helmet group compared with the mask group (no patients vs. 14 patients (21%), p = .002). The helmet allowed the continuous application of NPSV for a longer period of time (p = .05). Length of stay in the intensive care unit, intensive care, and hospital mortality were not different. NPSV by helmet successfully treated hypoxemic ARF, with better tolerance and fewer complications than facial mask NPSV.

5 May 2014 in Critical Care
Verified
Journal Article
Open access
PDF file
GPGennaro De Pascale
Gennaro De Pascale
LMLuca Montini
Luca Montini
MPMariano Alberto Pennisi
Mariano Alberto Pennisi
VBValentina Bernini
Valentina Bernini
RMRiccardo Maviglia
Riccardo Maviglia
MAMassimo Antonelli
Massimo Antonelli
Introduction: The high incidence of multidrug-resistant (MDR) bacteria among patients admitted to ICUs has determined an increase of tigecycline (TGC) use for the treatment of severe infections. Many concerns have been raised about the efficacy of this molecule and increased dosages have been proposed. Our purpose is to investigate TGC safety and efficacy at higher than standard doses. Methods: We conducted a retrospective study of prospectively collected data in the ICU of a teaching hospital in Rome. Data from all patients treated with TGC for a microbiologically confirmed infection were analyzed. The safety profile and efficacy of high dosing regimen use were investigated. Results: Over the study period, 54 patients (pts) received TGC at a standard dose (SD group: 50 mg every 12 hours) and 46 at a high dose (HD group: 100 mg every 12 hours). Carbapenem-resistant Acinetobacter.baumannii (blaOXA-58 and blaOXA-23 genes) and Klebsiella pneumoniae (blaKPC-3 gene) were the main isolated pathogens (n = 79). There were no patients requiring TGC discontinuation or dose reduction because of adverse events. In the ventilation-associated pneumonia population (VAP) subgroup (63 patients: 30 received SD and 33 HD), the only independent predictor of clinical cure was the use of high tigecycline dose (odds ratio (OR) 6.25; 95% confidence interval (CI) 1.59 to 24.57; P = 0.009) whilst initial inadequate antimicrobial treatment (IIAT) (OR 0.18; 95% CI 0.05 to 0.68; P = 0.01) and higher Sequential Organ Failure Assessment (SOFA) score (OR 0.66; 95% CI 0.51 to 0.87; P = 0.003) were independently associated with clinical failure. Conclusions: TGC was well tolerated at a higher than standard dose in a cohort of critically ill patients with severe infections. In the VAP subgroup the high-dose regimen was associated with better outcomes than conventional administration due to Gram-negative MDR bacteria.

1 January 2004 in Anesthesiology
Verified
Journal Article
Closed access
MAMassimo Antonelli
Massimo Antonelli
MPMariano Alberto Pennisi
Mariano Alberto Pennisi
PPPaolo Pelosi
Paolo Pelosi
CGCesare Gregoretti
Cesare Gregoretti
VSVincenzo Squadrone
Vincenzo Squadrone
GCGiorgio Conti
Giorgio Conti
Background: Noninvasive positive pressure ventilation (NPPV) with a facemask (FM) is effective in patients with acute exacerbation of their chronic obstructive pulmonary disease. Whether it is feasible to treat these patients with NPPV delivered by a helmet is not known. Methods: Over a 4-month period, the authors studied 33 chronic obstructive pulmonary disease patients with acute exacerbation who were admitted to four intensive care units and treated with helmet NPPV. The patients were compared with 33 historical controls treated with FM NPPV, matched for simplified acute physiologic score (SAPS II), age, PaCO2, pH, and PaO2:fractional inspired oxygen tension. The primary endpoints were the feasibility of the technique, improvement of gas exchange, and need for intubation. Results: The baseline characteristics of the two groups were similar. Ten patients in the helmet group and 14 in the FM group (P = 0.22) were intubated. In the helmet group, no patients were unable to tolerate NPPV, whereas five patients required intubation in the FM group (P = 0.047). After 1 h of treatment, both groups had a significant reduction of PaCO2 with improvement of pH; PaCO2 decreased less in the helmet group (P = 0.01). On discontinuing support, PaCO2 was higher (P = 0.002) and pH lower (P = 0.02) in the helmet group than in the control group. One patient in the helmet group, and 12 in the FM group, developed complications related to NPPV (P < 0.001). Length of intensive care unit stay, intensive care unit, and hospital mortality were similar in both groups. Conclusions: Helmet NPPV is feasible and can be used to treat chronic obstructive pulmonary disease patients with acute exacerbation, but it does not improve carbon dioxide elimination as efficiently as does FM NPPV.